Posted on: Monday, 26 October 2009, 16:00 CDT SAN FRANCISCO, Oct. 26 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will hold a teleconference at 8:30 a.m. Eastern Time tomorrow, Tuesday, October 27, to discuss partnering plans for MDV3100, Medivation's investigational drug which is currently in Phase 3 testing for the treatment of prostate cancer. Teleconference/Webcast Details To participate in the live call on Tuesday, October 27, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), please dial 888-280-4443 for domestic callers and 1-719-457-2638 for international callers. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. About Medivation Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel... [read full story]
|
RELATED
|
|
Chronicle Staff and News Services Wednesday, October 28, 2009 Prostate drug -- San Francisco's Medivation Inc. will receive a cash payment of $110 million from Astellas Pharma Inc. of Japan as part of a global agreement to...
Oct 29, 2009 (Datamonitor via COMTEX) -- Astellas Pharma, a Japanese pharmaceutical company, and Medivation, a US-based biopharmaceutical company, have entered into a global agreement to develop and commercialize MDV3100,...
Astellas Pharma Inc. and a U.S. pharmaceutical firm said Wednesday they have agreed to develop and commercialize worldwide a drug to treat prostate cancer. The Japanese drugmaker and Medivation Inc. will work on a...
Thursday 29th October, 03:25 AM JST TOKYO — Japanese drugmaker Astellas Pharma Inc and Medivation Inc, a U.S. biopharmaceutical firm, said Wednesday they have agreed to develop and commercialize worldwide a drug to treat...
SAN FRANCISCO, Oct. 28 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that it will host a teleconference and webcast with management to discuss third quarter 2009 financial results and provide a general business...
Medivation, Inc. today announced that it will host a teleconference and webcast with management to discuss third quarter 2009 financial results and provide a general business update on Wednesday, November 4, 2009, at 4:30 p.m.
SAN FRANCISCO, Oct. 28 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss third quarter 2009 financial results and provide a...
Astellas Pharma Inc. ("Astellas") and Medivation, Inc. announced today that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer....
Japanese drugmaker Astellas Pharma Inc. and Medivation Inc., a U.S. biopharmaceutical firm, said Wednesday they have agreed to develop and commercialize worldwide a drug to treat prostate cancer. According to the agreement, the...
San Francisco Business Times - by Medivation (NASDAQ: MDVN) will receive $110 million upfront from Astellas and could get $335 million for the drug reaching development and regulatory milestones. It would receive another $320...
